Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiationDosimetric factors and survival in lung cancer

Radiotherapy and Oncology

Volumn 119, Issue 3, 2016, Pages 495-500

  Tucker, Susan L ^a   Liu, Anwen ^b   Gomez, Daniel ^a   Tang, Ling Long ^c   Allen, Pamela ^a   Yang, Jinzhong ^a   Liao, Zhongxing ^a   Grosshans, David ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NANCHANG UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Chemoradiation; Heart radiation; Lung radiation; Non small cell lung cancer

Indexed keywords

PLATINUM;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL OUTCOME; COHORT ANALYSIS; CONFORMAL RADIOTHERAPY; DOSIMETRY; FEMALE; HEART DOSE; HISTOGRAM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LINEAR ACCELERATOR; LUNG DOSE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; RADIOTHERAPY PLANNING SYSTEM; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT PLANNING; TUMOR VOLUME; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; HEART; LUNG; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RADIATION RESPONSE; RADIOTHERAPY DOSAGE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FEMALE; HEART; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES;

EID: 84966862672     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.04.025     Document Type: Article

References (27)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
2. [2] Brown, T., Pilkington, G., Boland, A., Oyee, J., Tudur Smith, C., Dundar, Y., et al. Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. Health Technol Assess 17 (2013), 1–99.
3. [3] Goldstraw, P., Ball, D., Jett, J.R., Le Chevalier, T., Lim, E., Nicholson, A.G., et al. Non-small-cell lung cancer. Lancet 378 (2011), 1727–1740.
4. [4] Nalbantov, G., Kietselaer, B., Vandecasteele, K., Oberije, C., Berbee, M., Troost, E., et al. Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiother Oncol 109 (2013), 100–106, 10.1016/j.radonc.2013.08.035 Epub Sep 14.
5. [5] Rancati, T., Ceresoli, G.L., Gagliardi, G., Schipani, S., Cattaneo, G.M., Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 67 (2003), 275–283.
6. [6] Wang, S., Liao, Z., Wei, X., Liu, H.H., Tucker, S.L., Hu, C.S., et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 66 (2006), 1399–1407.
7. [7] Bradley, J.D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16 (2015), 187–199.
8. [8] Marks, L.B., Bentzen, S.M., Deasy, J.O., Kong, F.M., Bradley, J.D., Vogelius, I.S., et al. Radiation dose–volume effects in the lung. Int J Radiat Oncol Biol Phys 76 (2010), S70–S76.
9. [9] Liao, Z.X., Komaki, R.R., Thames, H.D. Jr., Liu, H.H., Tucker, S.L., Mohan, R., et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 76 (2010), 775–781.
10. [10] Minami-Shimmyo, Y., Ohe, Y., Yamamoto, S., Sumi, M., Nokihara, H., Horinouchi, H., et al. Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer. J Thorac Oncol 7 (2012), 177–182.
11. [11] Morota, M., Gomi, K., Kozuka, T., Chin, K., Matsuura, M., Oguchi, M., et al. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys 75 (2009), 122–128.
12. [12] Rodrigues, G., Lock, M., D'Souza, D., Yu, E., Van Dyk, J., Prediction of radiation pneumonitis by dose–volume histogram parameters in lung cancer–a systematic review. Radiother Oncol 71 (2004), 127–138.
13. [13] Inoue, A., Kunitoh, H., Sekine, I., Sumi, M., Tokuuye, K., Saijo, N., Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 49 (2001), 649–655.
14. [14] Farr, K.P., Khalil, A.A., Knap, M.M., Moller, D.S., Grau, C., Development of radiation pneumopathy and generalised radiological changes after radiotherapy are independent negative prognostic factors for survival in non-small cell lung cancer patients. Radiother Oncol 107 (2013), 382–388, 10.1016/j.radonc.2013.04.024 Epub May 29.
15. [15] Darby, S.C., McGale, P., Taylor, C.W., Peto, R., Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6 (2005), 557–565.
16. [16] Lally, B.E., Detterbeck, F.C., Geiger, A.M., Thomas, C.R. Jr., Machtay, M., Miller, A.A., et al. The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Cancer 110 (2007), 911–917.
17. [17] Group PM-aT. Postoperative radiotherapy for non-small cell lung cancer (review). The Cochrane Library. 2005; 2005.
18. [18] Cella, L., D'Avino, V., Palma, G., Conson, M., Liuzzi, R., Picardi, M., et al. Modeling the risk of radiation-induced lung fibrosis: irradiated heart tissue is as important as irradiated lung. Radiother Oncol 117 (2015), 36–43, 10.1016/j.radonc.2015.07.051 Epub Aug 12.
19. [19] Werner-Wasik, M., Swann, R.S., Bradley, J., Graham, M., Emami, B., Purdy, J., et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93–11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70 (2008), 385–390.
20. [20] Moreno-Jimenez, M., Aristu, J., Lopez-Picazo, J.M., Ramos, L.I., Gurpide, A., Gomez-Iturriaga, A., et al. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation. Radiother Oncol 88 (2008), 342–350.
21. [21] Bradley, J.D., Ieumwananonthachai, N., Purdy, J.A., Wasserman, T.H., Lockett, M.A., Graham, M.V., et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52 (2002), 49–57.
22. [22] Morgensztern, D., Waqar, S., Subramanian, J., Gao, F., Trinkaus, K., Govindan, R., Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. J Thorac Oncol 7 (2012), 1479–1484.
23. [23] Minsky, B.D., Pajak, T.F., Ginsberg, R.J., Pisansky, T.M., Martenson, J., Komaki, R., et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20 (2002), 1167–1174.
24. [24] Curran, W.J. Jr., Paulus, R., Langer, C.J., Komaki, R., Lee, J.S., Hauser, S., et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103 (2011), 1452–1460.
25. [25] Bradley, J., Graham, M.V., Winter, K., Purdy, J.A., Komaki, R., Roa, W.H., et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61 (2005), 318–328.
26. [26] Chang, J.Y., Komaki, R., Wen, H.Y., De Gracia, B., Bluett, J.B., McAleer, M.F., et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 80 (2011), 1350–1357.
27. [27] Hatakenaka, M., Yonezawa, M., Nonoshita, T., Nakamura, K., Yabuuchi, H., Shioyama, Y., et al. Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: magnetic resonance evaluation. Int J Radiat Oncol Biol Phys 83 (2012), e67–e73.